The FDA-approved schizophrenia and bipolar disorder therapy met the primary and secondary endpoint in a Phase III “withdrawal ...

周三，高盛更新了对Intra-Cellular Therapies (NASDAQ:ITCI)股票的展望，将目标价从74美元上调至79美元，同时维持中性评级。该公司2024年第三季度收入报告为1.754亿美元，略高于FactSet consensus的1.723亿美元预期，与高盛的1.752亿美元估计基本一致。Intra-Cellular还调整了2024年全年收入指引，现预计在6.65亿美元至6.

Intra-Cellular Therapies (ITCI) stock gains as the company raised outlook for its lead product Caplyta after better than ...

Having raised the full-year sales guidance for Caplyta (lumateperone) a week ago, Intra-Cellular Therapeutics has reported positive topline data from a Phase III trial of the therapy for ...

Intra-Cellular Therapies’ atypical antipsychotic medication Caplyta has been on a roll, delivering fast commercial growth and coming up triumphant in yet another late-stage trial. | Intra-Cellular ...

Intra-Cellular Therapies has announced positive results from Study 304 evaluating the efficacy and safety of Caplyta (lumateperone) 42mg for the prevention of relapse in adult patients with ...

Needham analyst Ami Fadia has maintained their bullish stance on ITCI stock, giving a Buy rating on October 22. Ami Fadia has given his Buy ...

Caplyta (lumateperone) is a brand-name oral capsule that’s prescribed for schizophrenia and bipolar depression in adults. As with other drugs, Caplyta can cause side effects, such as sleepiness ...

CAPLYTA Q3 2024 net product sales were $175.2 million, compared to $125.8 million for the same period in 2023, representing a 39% ...

Detailed price information for Intra-Cellular Ther (ITCI-Q) from The Globe and Mail including charting and trades.